Salvinorin B methoxymethyl ether
| Clinical data | |
|---|---|
| Other names | 2-O-Methoxymethylsalvinorin B; 2-MMSB |
| Drug class | κ-Opioid receptor agonist; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30O8 |
| Molar mass | 434.485 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Salvinorin B methoxymethyl ether, also known as 2-O-methoxymethylsalvinorin B (2-MMSB) is a semisynthetic analogue of the natural product salvinorin A which is used in scientific research.
It has a longer duration of action of around 2 to 3 hours, compared to less than 30 minutes for salvinorin A, and has increased affinity and potency at the κ-opioid receptor. It is prepared from salvinorin B. The crystal structure is almost superimposable with that of salvinorin A. Structures bound to the κ-opioid receptor have also been reported.
Salvinorin B methoxymethyl ether has a Ki of 0.60 nM at the κ opioid receptor, and is around five times more potent than salvinorin A in animal studies, although it is still only half as potent as its ethoxymethyl ether homologue, salvinorin B ethoxymethyl ether (2-O-ethoxymethylsalvinorin B; 2-EMSB; "symmetry").
The drug was encountered online as a novel designer drug in 2020.